Coronaviruses are a group of related viruses that cause diseases in mammals and birds. In humans, coronaviruses cause respiratory tract infections that can be mild, such as some cases of the common cold (among other possible causes, predominantly rhinoviruses), and others that can be lethal, such as SARS, MERS, and COVID-19. Symptoms in other species vary: in chickens, they cause an upper respiratory tract disease, while in cows and pigs they cause diarrhea.
There are yet to be vaccines or antiviral drugs to prevent or treat human coronavirus infections. We intend to use our Antibody - Vaccine Therapy to produce COVID-19 Antibodies from chicken eggs, which can then be administered orally and as a nasal spray to mitigate effects of exposure and to reduce recovery time in suffering patients.
Advantages over other treatments:
Much quicker to market:
Vaccines are relatively simple to engineer and some COVID-19 Vaccines are already starting human trials.
Unfortunately vaccine human safety issues typically require 18 months to complete. Furthermore, as preventive therapy, everyone needs to be vaccinated. It takes time to prepare and administer that many doses.
Our Antibodies can be produced in less time than a typical human vaccine, in amounts to easily cover potential high exposure situations such as front line workers and recently infected patients. These Antibodies can also be used to temporarily protect individuals when circulating in public areas or events.
Safety issues have been addressed in previous trials in animals and humans. This treatment is considered GRAS (Generally Regarded As Safe) by the FDA.
Better efficacy:
Antibody - Vaccine Therapy depends on the use of actual Antibodies, already produced by another source, to inhibit or fight the infection. We have shown efficacy in animals with our registered E. Coli Veterinary Biologics and in humans with our ongoing C Difficile phase 2 clinical trial.
Vaccines depend on a solid immune response by the host to be effective. Unfortunately those individuals most adversly affected by Coronavirus do not respond efficiently to vaccine stimulation.
For more information and how to contribute to the largest People-Powered campaign ever, please see www.MediEgg.com
Clostridium Difficile Antibody
The Super-bug Clostridium Difficile is a gram positive, spore forming bacteria known primarily for causing antibiotic associated diarrhea in patients admitted to hospitals and residents of health care facilities. The rate of incidence and severity of C. diff infections (CDI) has risen, annually affecting between 1 – 3 million people in North America and Europe. In severe cases, symptoms include pseudo membranous colitis, bowel perforation, and death. About 30,000 deaths annually in the USA are linked to CDI (CDC report: January 2015), with over 90% of these being patients 65 years of age or older. CDI is responsible for more deaths than all other intestinal infections combined.
Current medical treatment constitutes the use of certain antibiotics at a cost of between $2,000 and $16,000 per patient. C. Diff however has proven resistant as the current therapy has failed to cure about 25-30% of patients and new strains have evolved with increasing resistance and higher virulence. With aging populations rising in both North America and European countries, increasing placements in acute care and long-term care environments and continued widespread use of antibiotics, Clostridium Difficile Infection presents a growing threat to public health. A new, effective treatment will represent a huge advance in medical science, where the annual health care cost of this disease in the United States alone is estimated at over $3 Billion.
For more information please see www.immunimed.com
Harnessing the power of Natural Passive Immunity
IMMUNADE is the Human adaptation of our Animal Health Veterinary Biologic, used to prevent diarrhea in young animals caused by E. Coli bacteria. Our processing technique allows it to also maintain its natural passive immunity and the natural antimicrobial enzyme, Lysozyme.
What is the gut Microbiome?
The gut microbiota consists of some 100 trillion mostly good and bad bacteria, normally coexisting in harmony. This number is about 10 times the number of cells in the human body, with 150 times the number of human genes. It has also been found that while all humans are genetically 99.99% the same, our gut microbiota is likely only 10-30% the same. And likely the reason we are all so different.
Recent research has shown that how goes these bugs, goes your health, with many studies showing the relationship of the gut microbiota to almost all human health disorders. In other words, “Keep your bugs happy and they'll keep you healthy.”
Microbiome Dysbiosis (MD) is when your bugs are not happy, or in scientific terms, the bad bacteria overgrow and cause problems.
The simplest form of MD is the bacterial infection involved in Traveler's Diarrhea, where an overgrowth of usually E. Coli bacteria produces a toxin that causes inflammation, resulting in digestive upset and diarrhea.
With IMMUNADE, we hypothesize that many health disorders are caused by Microbiome Dysbiosis. If we can stop this bad bug overgrowth, we can stop the disorder. IMMUNADE also provides a daily dose of extra immunity to your gut, allowing your Immune System to better concentrate on health issues in the rest of your body.